Citizens reiterates Market Outperform rating on Larimar stock ahead of FA discussion

Larimar Therapeutics (LRMR) is facing mixed analyst sentiment despite a 116% six-month stock surge, as promising efficacy data for its Friedreich’s Ataxia treatment, showing patients achieving over 50% of healthy frataxin levels, is tempered by safety concerns. Seven cases of anaphylaxis were reported in its open-label study, leading firms like Citizens, JMP Securities, and Leerink Partners to maintain Outperform ratings and an $18 price target, while Jones Trading adjusted its target down to $7 from $10 due to the safety profile, highlighting the market's ongoing evaluation of the drug's risk-benefit. Citizens will host a virtual discussion on Friedreich's Ataxia treatments, including Larimar's data, in October 2025.

Analysis

Larimar Therapeutics (LRMR) presents a classic high-risk, high-reward biotech profile, with analyst sentiment diverging significantly based on the weighting of efficacy versus safety data for its Friedreich’s Ataxia treatment, nomlabofusp. On one hand, the drug demonstrates promising efficacy, with an open-label study showing participants achieved skin frataxin levels exceeding 50% of the median in healthy individuals. This positive data underpins bullish 'Market Outperform' ratings from firms like Citizens, JMP Securities, and Leerink Partners, which all maintain an $18 price target. On the other hand, a significant safety overhang exists, with seven cases of anaphylaxis reported among 39 study participants. This safety concern has been explicitly cited by Jones Trading, which consequently reduced its price target to $7.00 from $10.00, and is likely a factor in the stock's recent 16% weekly decline. The current share price of $4.28 reflects this deep uncertainty, trading at a substantial discount to the bull-case targets but closer to the risk-adjusted view, despite the stock's 116% surge over the prior six months. An upcoming virtual discussion with the Friedreich’s Ataxia Research Alliance CEO represents a key catalyst, offering a platform for the company to address the critical risk-benefit questions.

Key Decisions for Investors

• Investors should recognize the binary risk profile of Larimar, where the significant upside implied by efficacy data and bullish $18 price targets is directly challenged by the unresolved anaphylaxis safety concerns from its Phase 2 study.
• The wide dispersion in analyst price targets, from $7 to $18, underscores the market's deep uncertainty; positions should be sized according to an individual's tolerance for the high volatility typical of clinical-stage biotech.
• Close monitoring of the upcoming virtual discussion with the FARA CEO is crucial, as management's ability to contextualize the safety events and outline a clear regulatory and mitigation strategy will be a key determinant of future stock performance.